Public Comment: Pediatric Antithrombotic Trials Guidance

Development of New Antithrombotic Drugs for Children (Part 1): Guidance from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis and the Pedi-ATLAS Group: Open for public review

The ISTH has recently drafted a guidance manuscript on the specific considerations for the development of new antithrombotic drugs for children, given the accumulating evidence from a comprehensive literature review. The guidance was developed by a panel of over 20 content experts.

The draft guidance is available for review HERE. Note: This manuscript is confidential and in draft form.

We now kindly ask the greater community of physicians, scientists, and allied health professionals to review and provide any comments by October 30, 2025.

1. Please enter your information, due to conflict of interest concerns, anonymous comments will not be accepted.
Comments will not be attributed, published or provided to anyone beyond the Guideline and Guidance Committee.

First Name *This question is required.

Last Name *This question is required.

Title

Institution *This question is required.

Country *This question is required.

Email Address *This question is required. This question requires a valid email address.

2. Please indicate any financial or intellectual conflicts of interest you may have related to your comments on this guideline: *This question is required.

3. To which section does your comment apply?

Page, line or figure number:

Comment:

4. To which section does your comment apply?

Page, line or figure number:

Comment:

5. To which section does your comment apply?

Page, line or figure number:

Comment:

6. To which section does your comment apply?

Page, line or figure number:

Comment:

7. To which section does your comment apply?

Page, line or figure number:

Comment:

Click the submit button below to send your comments. If you would like to make additional comments, you may submit additional forms.